Search for: "Cephalon Inc." Results 1 - 20 of 176
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
11 Jan 2022, 11:45 am by luiza
In 2015, AstraZeneca and Cephalon paid a total of $54 million to resolve claims that they also improperly reduced AMPs by wrongfully accounting for service fees they paid to wholesalers. [read post]
11 Jan 2022, 11:45 am by luiza
In 2015, AstraZeneca and Cephalon paid a total of $54 million to resolve claims that they also improperly reduced AMPs by wrongfully accounting for service fees they paid to wholesalers. [read post]
9 Jan 2022, 8:31 pm by James Kwong
   Patents In the United States, PatentlyO reported that Apotex Inc. recently issued a petition for writ of certiorari in the case of Apotex Inc. v Cephalon, Inc., asking the Supreme Court to revisit motivation to combine, obvious to try and whether the non-obvious contribution needs to be an improvement over the prior art. [read post]
14 Nov 2018, 11:33 am by taotiadmin
The Department of Justice recently announced that Cephalon, Inc., a biopharmaceutical company, will pay $425 million to settle “off-label marketing”… The post $425 Million Settlement In “Off-Label Marketing” Case appeared first on TZ Legal - Fraud Fighters. [read post]
30 Nov 2017, 8:59 pm by Brenda Fulmer
Counsel representing several Plaintiffs filed for consolidation of the actions of state, county, and municipal governments and other agencies against opiate manufacturers Purdue Pharma, Teva/Cephalon, Janssen, Endo, Actavis, and Mallinckrodt and distributors McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc. [read post]
28 Aug 2017, 10:11 pm by Barry Barnett
Cephalon, Inc., No. 06-c-1797, ECF 1072 (E.D. [read post]
28 Aug 2017, 10:11 pm by Barry Barnett
Cephalon, Inc., No. 06-c-1797, ECF 1072 (E.D. [read post]
28 Aug 2017, 10:11 pm by Barry Barnett
Cephalon, Inc., No. 06-c-1797, ECF 1072 (E.D. [read post]
28 Aug 2017, 10:11 pm by Barry Barnett
Cephalon, Inc., No. 06-c-1797, ECF 1072 (E.D. [read post]
11 Apr 2016, 2:32 pm by Robert Reznick
  The FTC’s complaint attacks two such settlements that Endo Pharmaceuticals Inc. and the Japan-based patent holder for one of the relevant patents reached with generic manufacturers Watson Laboratories (and Watson’s current owner, Allergan plc) and Impax Laboratories, to settle Hatch-Waxman litigation involving Endo’s two most important products—the pain relievers Opana ER® and Lidoderm®.[2]  The FTC’s complaint, and its simultaneous… [read post]
8 Dec 2015, 2:22 pm by Ben Vernia
  AstraZeneca LP and Cephalon Inc. paid the United States $26.7 million and $4.3 million, respectively, in separate settlements for allegedly underpaying rebates owed under the Medicaid Drug Rebate Program. [read post]